Exenatide

What Exenatide does

Exenatide is a GLP-1 medicine first approved for type 2 diabetes in 2005. Twice-daily and weekly products have different dosing and kidney limits. Many branded products are now withdrawn or discontinued. Trials support glucose lowering, but EXSCEL did not prove fewer major heart events. Stomach upset, dehydration and kidney injury are key risks.

• Exenatide is approved for type 2 diabetes in adults, though some brand-name versions have since been withdrawn. (Drug label)
• In a trial, the weekly form lowered the long-term blood sugar score by 1.9 points, versus 1.5 for the twice-daily form. (Studied in a trial)
• In diabetes trials, people also lost some weight, but it is not approved for weight loss. (Studied in a trial)

Uses in the sources

• Immediate-release exenatide has an adult type 2 diabetes label; weekly labels also included ages 10 and older. Approval is separate from current supply. (Drug label) (source)
• Weight reduction occurred in diabetes trials; exenatide has no US weight-management indication. (Studied in a trial) (source)
• The 2025 phase 3 Parkinson's trial found no slowing of motor decline over 96 weeks. (Studied in a trial) (source)

Exenatide dosage

Typical reported dose: 5 mcg twice a day, then 10 mcg if needed

• Immediate release: 5 then 10 mcg twice daily: 5 mcg twice daily for 1 month, then 10 mcg twice daily if needed after 1 month twice daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes. (source)
• Historical weekly depot: 2 mg: 2 mg once weekly once weekly, under the skin. Drug label. Studied in: Weekly exenatide diabetes label; BCise included adults and ages 10+. (source)
• Dose finding: 2.5 mcg twice daily: 2.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 5 mcg twice daily: 5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 7.5 mcg twice daily: 7.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 10 mcg twice daily: 10 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to store Exenatide

Comes as: Immediate release: 250 mcg/mL ready-made pens delivering 5 or 10 mcg, Historical BCise: 2 mg/0.85 mL microsphere suspension in a single-use autoinjector.

Mixed with: None for immediate-release pens or BCise. BCise is premixed in an oil-based vehicle; do not add water..

• For BCise, allow at least 15 minutes to reach room temperature, then shake vigorously for at least 15 seconds.
• BCise must look uniformly cloudy, white to off-white, without residual clumps. Follow the device instructions.
• No supported grey-vial sizes, water volumes or home-mixed shelf life were found.

Before mixing: Refrigerate at 2–8°C; do not freeze. Store BCise flat in its carton, protected from light.

After mixing: Immediate-release pen: after first use ≤25°C, discard at 30 days. BCise: ≤30°C for a total of 4 weeks; use immediately after preparing.

Exenatide side effects and risks

Reported side effects

• Nausea with immediate release: Pooled twice daily trials: 44% versus placebo 18%., moderate (source)
• Vomiting with immediate release: 13% versus placebo 4%., moderate (source)
• Diarrhea with immediate release: 13% versus placebo 6%., moderate (source)
• Weekly depot injection-site nodules: BCise pooled trials: 10.5%; nausea 8.2%., moderate. Persistent, painful, blistered or draining nodules need assessment. (source)
• Low blood sugar: With metformin plus sulfonylurea: 10 mcg 28%, 5 mcg 19%, placebo 13%., serious (source)
• Pancreatitis: Acute pancreatitis, including fatal or necrotizing cases, is reported; no reliable postmarketing rate., serious (source)
• Gallbladder disease: EXSCEL: 1.9% versus placebo 1.4%., serious (source)
• Kidney injury: Risk rises with dehydration or reduced kidney clearance; dialysis has been needed in reported cases., serious (source)
• Immune-related low platelets: Exenatide dependent antibodies can cause severe bleeding; reported postmarketing., serious (source)
• Serious injection-site injury: Abscesses, cellulitis and tissue death have been reported with weekly depot products., serious (source)
• Thyroid C-cell tumors with extended release: Weekly depot has a boxed rodent tumor warning; immediate release exenatide does not carry this boxed warning., serious (source)
• Severe allergic reaction: Anaphylaxis and angioedema have been reported; frequency unknown., serious (source)

Stop and get help if

• Severe, persistent belly pain, especially spreading to the back: Stop the drug and seek urgent care for possible pancreatitis.
• Face or throat swelling, trouble breathing, or collapse: Call emergency services now; do not take another dose.
• Confusion, seizure, fainting or low blood sugar that does not resolve: Get emergency care. If awake and able to swallow, use fast sugar while help is arranged.
• Repeated vomiting, inability to keep fluids down, or very little urine: Seek urgent assessment for dehydration and kidney injury.
• Upper-right belly pain with fever, yellow skin or pale stools: Seek urgent care for possible gallbladder or bile-duct disease.
• Sudden vision loss or a major new change in vision: Get urgent same-day eye or emergency assessment.
• Chest pain, marked breathlessness or fainting: Call emergency services now.
• New unusual bruising, pinpoint rash, bleeding or blood in stool: Stop exenatide and seek urgent care for possible immune low platelets.
• Painful, enlarging, blistered or draining depot injection site: Seek prompt care; serious injection-site injury sometimes needs surgery.

Who should avoid it

• pregnant: Weight loss is unsuitable; fetal-risk data are limited and animal findings raise concern.
• tryingToConceive: Review a stopping plan before conception; no safe conception interval was established in the extracted sources.
• breastfeeding: Human milk and infant-safety data are inadequate.
• under18: Some labeled diabetes or obesity uses include children; this is not a blanket pediatric label ban.
• mtcOrMen2: The MTC/MEN2 contraindication and boxed warning apply to the extended-release depot product. Immediate-release exenatide has its own product-specific contraindications. Weekly depot exenatide is contraindicated with MTC/MEN2. This caution applies across the profile; immediate release lacks this boxed warning.
• other: Do not re-expose after a serious allergic reaction to the drug or its ingredients.
• pancreatitisHistory: Past pancreatitis needs review; stop and urgently assess persistent severe abdominal pain.
• gallbladderDisease: Gallstones or previous gallbladder inflammation increase the need to assess new upper-abdominal pain.
• gastroparesis: Severe gastroparesis is a label reason to avoid use; these medicines further slow stomach emptying.
• eatingDisorderHistory: Listed as a reason to avoid it.
• kidneyDisease: Kidney function and hydration need review, especially with vomiting or diarrhea.
• liverDisease: Clinical experience in severe liver impairment is limited; review the specific product and other medicines.
• diabeticRetinopathy: Rapid glucose improvement can temporarily worsen diabetic eye disease; arrange appropriate eye follow-up.
• surgeryPlanned: Tell the anesthesia team. Delayed stomach emptying can leave food in the stomach despite fasting.
• diabetes: Review glucose monitoring and insulin or sulfonylurea doses. Do not rapidly stop insulin.
• other: Immediate release is not recommended with creatinine clearance <30 mL/min or end-stage kidney disease.
• other: Weekly BCise is not recommended below eGFR 45 mL/min/1.73 m².
• other: Prior exenatide-induced immune thrombocytopenia is a contraindication; re-exposure can trigger severe bleeding.

Interactions

• Insulin: Low blood sugar risk can rise. Insulin adjustment needs glucose readings; rapid withdrawal can cause ketoacidosis.
• Sulfonylureas and related insulin-releasing drugs: Low blood sugar can increase; a clinician may need to lower the companion drug dose.
• Another GLP-1 or GLP-1/GIP medicine: Avoid duplicate incretin therapy. Switching guidance stops the previous product rather than stacking both.
• DPP-4 inhibitors: Routine combination is not recommended because it adds little glucose benefit over GLP-1 therapy alone.
• Time-sensitive oral medicines: Slower stomach emptying can alter absorption timing; the effect is medicine-specific. Review critical oral drugs, especially with vomiting or poor intake.
• Warfarin: Raised INR, sometimes with bleeding, has been reported. Check INR frequently after starting or changing exenatide.
• Oral contraceptives and time-critical antibiotics: With immediate release, take at least 1 hour before exenatide when rapid absorption matters; check product-specific timing.

Product quality risks

• Online GLP-1 products can contain the wrong amount, a different drug or contamination. A seller’s purity claim does not establish sterile injectable quality.
• Three online semaglutide vials had 28.56–38.69% excess drug and endotoxin. Those samples were not this compound.
• No direct online exenatide assay survey was found. A plain powder cannot reproduce the weekly or monthly release system.

What to expect

334 registered interventional records found before the cutoff, including planned trials and comparator arms. Selected major reports appear below; this is not a completed-trial count.

Key studies

• Early weight-based injections: Across active regimens, reductions ranged 0.7–1.1%; 15% reached HbA1c <7% versus 4% with placebo. (source)
• Twice-daily dose finding: 2.5/5/7.5/10 mcg: −0.7/−0.7/−1.4/−1.8 kg; placebo 0.0 kg. (source)
• AMIGO: added to a sulfonylurea: 10 mcg −0.86%; 5 mcg −0.46%; placebo +0.12%. (source)
• AMIGO: added to metformin: 10 mcg −0.78%; 5 mcg −0.40%; placebo +0.08%. (source)
• AMIGO: metformin plus sulfonylurea: 10 mcg −0.8%; 5 mcg −0.6%; placebo +0.2%. (source)
• Weekly depot dose finding: 0.8 mg −1.4%; 2 mg −1.7%; placebo +0.4%. (source)

Exenatide FAQ

• Is Exenatide FDA-approved? Yes: Byetta, historical (adult type 2 diabetes; NDA021773 approval withdrawn effective September 3, 2025.); Bydureon, historical (weekly type 2 diabetes depot; US approval withdrawn.); Bydureon BCise, historical (historical type 2 diabetes depot, ages 10+. NDA209210 appears in withdrawal notices effective September 3, 2025 and April 8, 2026; the later notice does not establish its first withdrawal.). Compound approval, brand withdrawal and supply differ. Generic label remains online; FDA lists discontinued products and a separate prescription NDA021919. Stock is unconfirmed.
• How do people take it? Under the skin, twice daily. Source: drug label.
• Can I take it with Metformin? Studied and reported diabetes pairing with immediate-release or weekly exenatide. Overlapping stomach upset can worsen hydration. Source: studied in a trial. Ask a doctor before combining anything.
• Is it banned in sport? No, it is not on the banned list (WADA 2026). The 2026 monitoring program names semaglutide and tirzepatide, not this drug. Approved GLP-1 medicines remain permitted.
• How do I store it once opened? Immediate-release pen: after first use ≤25°C, discard at 30 days. BCise: ≤30°C for a total of 4 weeks; use immediately after preparing.